Back to People & Entities
Merrell Dow Pharmaceuticals, Inc.
Organization
4
Total Mentions
4
Documents
2
Connected Entities
Merrell Dow Pharmaceuticals, Inc. appears in the Epstein files exclusively as a legal citation in court documents from Ghislaine Maxwell's trial, not as an entity connected to the case.
All four mentions reference the landmark Supreme Court case Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), which established the standard for admitting expert testimony in federal courts. The company is cited in legal motions to exclude expert witnesses under Federal Rule of Evidence 702, specifically in documents discussing evidentiary standards for Dr. Lisa Rocchio's testimony. Merrell Dow Pharmaceuticals was a pharmaceutical company (formed in 1980 when Dow Chemical acquired Merrell's prescription drug division, later merged into Marion Merrell Dow in 1989, and eventually acquired by Hoechst AG in 1995) that became famous as the defendant in the Daubert case involving the drug Bendectin and alleged birth defects.
Key Highlights
- •All mentions are legal citations to Daubert v. Merrell Dow Pharmaceuticals, Inc., not references to the company itself
- •The citations appear in defense motions to exclude expert testimony in Maxwell's trial
- •The company has no substantive connection to Epstein, Maxwell, or the underlying case—it's simply part of a standard legal citation
Frequently Asked Questions
Related Links
Books for Further Reading
Perversion of Justice: The Jeffrey Epstein Story
Julie K. Brown
Investigative journalism that broke the Epstein case open
Filthy Rich: The Jeffrey Epstein Story
James Patterson
Bestselling account of Epstein's crimes and network
Relentless Pursuit: My Fight for the Victims of Jeffrey Epstein
Bradley J. Edwards
Victims' attorney's firsthand account
Document Mentions (4)
1 mention
ense's motion to exclude the Government's expert witness, Dr. Lisa Rocchio, pursuant to Federal Rule of Evidence 702 and the standard in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Dkt. No. 386. The Government filed a response brief, Dkt. No. 397, and Defendant filed a reply, Dkt. No. 398. The Court conduc
Page: EFTA00016471 →1 mention
ion under Federal Rule of Evidence 412, Dkt. No. 378, the Defendant's motion in limine to exclude under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), Dkt. No. 386, and the other outstanding issues that overlap with these two motions as discussed at the November 1, 2021 confe
Page: EFTA00027649 →1 mention
ion under Federal Rule of Evidence 412, Dkt. No. 378, the Defendant's motion in limine to exclude under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), Dkt. No. 386, and the other outstanding issues that overlap with these two motions as discussed at the November 1, 2021 confe
Page: EFTA00027654 →Sponsored
1 mention
ion under Federal Rule of Evidence 412, Dkt. No. 378, the Defendant's motion in limine to exclude under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), Dkt. No. 386, and the other outstanding issues that overlap with these two motions as discussed at the November I, 2021 confe
Page: EFTA00028165 →Sponsored
